Paschalis Karakasis
Overview
Explore the profile of Paschalis Karakasis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
147
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Karakasis P, Patoulias D, Rizzo M, Fragakis N, Mantzoros C
Diabetes Obes Metab
. 2025 Feb;
PMID: 39950216
Background And Aims: Adequate lipid control has emerged as a key factor in the prevention and management of chronic kidney disease (CKD). Remnant cholesterol (RC), a lipoprotein with an established...
12.
Theofilis P, Oikonomou E, Karakasis P, Pamporis K, Dimitriadis K, Kokkou E, et al.
Liver Int
. 2025 Feb;
45(3):e70016.
PMID: 39898512
Background And Aims: Liver-related complications are frequent in patients with metabolic diseases, with limited treatment options currently available. This systematic review and meta-analysis aimed to assess the effect of fibroblast...
13.
Karakasis P, Theofilis P, Patoulias D, Schuermans A, Vlachakis P, Klisic A, et al.
Eur J Clin Invest
. 2025 Jan;
e14392.
PMID: 39868862
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) commonly leads to heart failure but has traditionally been an exclusion criterion in randomized clinical trials (RCTs) of sodium-glucose cotransporter 2 inhibitors (SGLT2i); therefore, the...
14.
Theofilis P, Oikonomou E, Vlachakis P, Karakasis P, Dimitriadis K, Sagris M, et al.
Curr Vasc Pharmacol
. 2025 Jan;
PMID: 39819408
Introduction: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as a groundbreaking class of antidiabetic medications renowned for their glucose-lowering effects and cardiovascular benefits. Recent studies have suggested that SGLT2 inhibitors...
15.
Karakasis P, Theofilis P, Vlachakis P, Korantzopoulos P, Patoulias D, Antoniadis A, et al.
Int J Mol Sci
. 2025 Jan;
26(1.
PMID: 39796066
Atrial fibrosis is a hallmark of atrial cardiomyopathy and plays a pivotal role in the pathogenesis of atrial fibrillation (AF), contributing to its onset and progression. The mechanisms underlying atrial...
16.
Theofilis P, Vlachakis P, Oikonomou E, Drakopoulou M, Karakasis P, Apostolos A, et al.
Biomedicines
. 2025 Jan;
12(12.
PMID: 39767820
Cancer therapy-related cardiac dysfunction (CTRCD) has emerged as a significant concern with the rise of effective cancer treatments like anthracyclines and targeted therapies such as trastuzumab. While these therapies have...
17.
Karakasis P, Patoulias D, Fragakis N, Mantzoros C
Metabolism
. 2024 Dec;
164:156113.
PMID: 39719170
Background And Aims: While glucagon-like peptide-1 receptor agonists (GLP-1RAs) effectively reduce body weight, their impact on lean mass remains uncertain. This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor...
18.
Teperikidis L, Karakasis P, Patoulias D, Boulmpou A, Kouzoukas D
Eur J Intern Med
. 2024 Nov;
PMID: 39613702
No abstract available.
19.
Patoulias D, Karakasis P, Ruza I, El-Tanani M, Rizzo M
Expert Opin Drug Saf
. 2024 Nov;
24(2):121-124.
PMID: 39610149
No abstract available.
20.
Astan R, Patoulias D, Ninic A, Dayanan R, Karakasis P, Mercantepe T, et al.
J Clin Med
. 2024 Nov;
13(22).
PMID: 39598120
: Non-dipper hypertension (HT), a condition in which blood pressure does not drop sufficiently at night compared to daytime, is considered a serious condition that increases the risk of cardiovascular...